CI
Catalan Institute of Oncology (ICO) at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Catalan Institute of Oncology (ICO) takes part in 4 sessions at ESMO 2026 in Madrid. Its program covers targeted therapy aimed at HER2 and DLL3 across cancers, and when to intensify treatment in metastatic hormone-sensitive prostate cancer, including PSMA-targeted radioligand therapy. It also reports a randomised trial of remote follow-up to encourage physical activity after haematological transplantation.
| Organization | ESMO 2026 Attendance |
|---|---|
CI Catalan Institute of Oncology (ICO) L'Hospitalet de Llobregat, Spain | |
Public cancer centre of the Catalan health system, with its main hospital in L'Hospitalet de Llobregat near Barcelona, Spain. | Satellite Sat Oct 24 13:35–14:05 Treatment evolution in mHSPC: Who needs treatment intensification? Genitourinary cancers Talk Sat Oct 24 16:00–16:15 Satellite Sat Oct 24 18:30–20:00 Satellite Sat Oct 24 18:30–18:35 Chair’s welcome and introductions Lung & thoracic cancers Satellite Sat Oct 24 18:55–19:05 HER2 across cancers: Unlocking broader therapeutic potential Lung & thoracic cancers Satellite Sat Oct 24 19:55–20:00 Chair’s closing remarks Lung & thoracic cancers Abstract Sun Oct 25 14:45–14:50 LBA46 - Niraparib and dostarlimab plus radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) patients (TTCC-2022-01 RADIAN). Sarcoma, CNS, head & neck and rare cancers |
Instantly find 20 buyers from Catalan Institute of Oncology (ICO)
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction